Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Blinatumomab for MRD+ Ph- B-ALL
NCT06886074Phase 2Recruiting
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Started Jan 2025; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06886074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886074.